Paul Stabach

A Research Associate/Lab Manager with 25 Years of Molecular/Cellular Biological experience from Yale, MIT, Baylor College of Medicine, Jefferson University, and University of Connecticut Health Center, currently focused on the design and implementation of novel enzyme biologics to treat debilitating pathologies associate with enzyme deficiency.

After an initial success in the Braddock lab with a rare disease of lethal vascular calcifications associated with ENPP1 deficiency called 'Generalized Arterial Calcification of Infancy' (GACI), he then published an article detailing how to improve the potency and longevity of any blood based enzyme biologic (Stabach et.al. Clin Transl Sci. 2020 Oct 16). He is now engineering a new enzyme biologic for the treatment of pathologies associate with the aberrant formation of neutrophil extracellular traps, or netosis. If successful, this biologic could have indications with several pathologies including Lupus, Acute Respiratory Distress Syndrome associated with COVID-19, Cancer metastasis, and coagulopathies such as Deep View Thrombosis and Disseminated Intravascular Coagulation.